Edwards Lifesciences, a medical technology firm, has reported a strong quarterly profit and revenue, exceeding analysts’ estimates. The company’s success can be attributed to the high demand for its artificial heart valves, particularly the transcatheter aortic valve replacement (TAVR) device.
Quarterly Performance
The TAVR device sales rose by 11.3% to $1.26 billion, surpassing the estimated $1.23 billion. The company’s quarterly revenue was $1.74 billion, higher than the estimated $1.70 billion. On an adjusted basis, Edwards earned 78 cents per share, compared to the estimated 74 cents.
Edwards Lifesciences has also raised the lower end of its 2026 sales growth forecast for TAVR devices to 8% from 7%, while maintaining the upper end at 9%. The company has kept its annual adjusted profit expectations in the range of $2.95 to $3.05 per share.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
